CN106573040B - 治疗异常皮肤瘢痕形成 - Google Patents

治疗异常皮肤瘢痕形成 Download PDF

Info

Publication number
CN106573040B
CN106573040B CN201480078924.1A CN201480078924A CN106573040B CN 106573040 B CN106573040 B CN 106573040B CN 201480078924 A CN201480078924 A CN 201480078924A CN 106573040 B CN106573040 B CN 106573040B
Authority
CN
China
Prior art keywords
apc
scar
skin
tgf
scarring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480078924.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN106573040A (zh
Inventor
克里斯托弗·约翰·杰克逊
薛妹朗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ZZ Biotech LLC
Original Assignee
ZZ Biotech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014901397A external-priority patent/AU2014901397A0/en
Application filed by ZZ Biotech LLC filed Critical ZZ Biotech LLC
Publication of CN106573040A publication Critical patent/CN106573040A/zh
Application granted granted Critical
Publication of CN106573040B publication Critical patent/CN106573040B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201480078924.1A 2014-04-16 2014-10-29 治疗异常皮肤瘢痕形成 Active CN106573040B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014901397 2014-04-16
AU2014901397A AU2014901397A0 (en) 2014-04-16 Treatment of abnormal cutaneous scarring
PCT/AU2014/050323 WO2015157791A1 (en) 2014-04-16 2014-10-29 Treatment of abnormal cutaneous scarring

Publications (2)

Publication Number Publication Date
CN106573040A CN106573040A (zh) 2017-04-19
CN106573040B true CN106573040B (zh) 2021-07-06

Family

ID=54323254

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480078924.1A Active CN106573040B (zh) 2014-04-16 2014-10-29 治疗异常皮肤瘢痕形成

Country Status (11)

Country Link
US (3) US20170042982A1 (enExample)
EP (1) EP3137102B1 (enExample)
JP (2) JP2017513944A (enExample)
CN (1) CN106573040B (enExample)
AU (1) AU2014391082B2 (enExample)
CA (1) CA2946028C (enExample)
DK (1) DK3137102T3 (enExample)
ES (1) ES2890675T3 (enExample)
PL (1) PL3137102T3 (enExample)
PT (1) PT3137102T (enExample)
WO (1) WO2015157791A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104394883B (zh) * 2012-07-04 2017-05-31 悉尼大学 炎性皮肤病症的治疗
US20170035862A1 (en) 2014-04-16 2017-02-09 Zz Biotech Llc Use of APC analogue for wound healing
CA3134041A1 (en) * 2019-03-19 2020-09-24 Figene, Llc Treatment of chronic obstructive pulmonary disease and lung degeneration using activated fibroblasts and exosome derivatives thereof
CN113073082A (zh) * 2021-03-19 2021-07-06 广州远想生物科技有限公司 TGF-β3间充质干细胞外泌体及其制备方法和应用
CN114788711A (zh) * 2022-04-26 2022-07-26 李娜 一种瘢痕评估方法及系统

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007820A2 (en) * 2003-07-08 2005-01-27 The Scripps Research Institute Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity
WO2008073603A2 (en) * 2006-10-31 2008-06-19 The Scripps Research Institute Dosing regimen of activated protein c and variants having reduced anticoagulant activity

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US4959318A (en) 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
EP0380508A4 (en) 1987-05-18 1991-04-03 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
US5084274A (en) 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
AT402260B (de) 1990-08-16 1997-03-25 Immuno Ag Protein c-hältige pharmazeutische präparation
US5571786A (en) 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
AT397615B (de) 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
WO1993009807A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4239150A1 (de) 1992-11-20 1994-05-26 Thomae Gmbh Dr K O-Acyl-4-phenyl-cyclohexanole, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
JP3043558B2 (ja) 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
AU2467395A (en) 1994-05-04 1995-11-29 Board Of Trustees Of The University Of Arkansas, The Novel ophthalmologic uses of protein c
PL195642B1 (pl) 1997-04-28 2007-10-31 Lilly Co Eli Sposób przetwarzania wodnego roztworu aktywowanego białka C
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
WO2001056532A2 (en) 2000-02-04 2001-08-09 The Scripps Research Institute Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)
AU2001232799A1 (en) 2000-02-11 2001-08-20 Eli Lilly And Company Protein c derivatives
ES2242740T3 (es) * 2000-03-28 2005-11-16 Eli Lilly And Company Proteina c activada para el tratamiento de pancreatitis.
AU1038802A (en) * 2000-10-18 2002-04-29 Maxygen Aps Protein c or activated protein c-like molecules
ES2384099T3 (es) * 2001-06-13 2012-06-29 The University Of Sydney Proteína C para cicatrización de heridas
WO2004041296A2 (en) 2002-11-06 2004-05-21 Novo Nordisk A/S Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
EP1477166B1 (de) * 2003-04-28 2006-08-23 Biofrontera Bioscience GmbH Verwendung von Riluzole kombiniert mit geeigneten Hilfs-und Zusatzstoffen zur Behandlung von Krankheiten, die durch eine Hyperproliferation von Keratinozyten gekennzeichnet sind, insbesondere Neurodermitis und Psoriasis
US9192657B2 (en) 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
US20070224150A1 (en) 2005-03-24 2007-09-27 Yongji Chung Growth factor for hair and skin treatment
CN101262880A (zh) * 2005-06-24 2008-09-10 德拉格雷丘尔公司 在影响呼吸道的炎症病状中气道施用组织因子途径抑制物
GR1005700B (el) 2006-09-01 2007-10-22 (40%) ����� �������� Τροπος αντιμετωπισης της 1ης φασης του εγκαυματοσσε μη σηπτικους ασθενεις με συνεχη ενδοφλεβια χορηγηση ενεργοποιημενης πρωτεινης-c για 48 ωρες με στοχο τη μειωση της τελικης εγκαυματικης βλαβης καιαυξηση της ταχυτητας επουλωσης κατα τα πρωτα επτα μετεγκαυματικα 24ωρα
GB0724231D0 (en) 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
ES2316312B1 (es) 2008-06-20 2010-02-08 Ignacio Umbert Millet Composicion farmaceutica dermatologica para el tratamiento de patologias de inflamacion de la piel, tales como por ejemplo dermatitis, dermatitis atopica, vitiligo, alopecia areata, acne, psoriasis y prurito,y combinaciones de las mismas.
EP2157176A1 (en) 2008-08-20 2010-02-24 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Protein C Variants
CN101912450A (zh) 2010-09-01 2010-12-15 吴业刚 一种治疗脚气皮炎的中西药组合物及其制备方法
CN104394883B (zh) * 2012-07-04 2017-05-31 悉尼大学 炎性皮肤病症的治疗
US20170035862A1 (en) 2014-04-16 2017-02-09 Zz Biotech Llc Use of APC analogue for wound healing

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007820A2 (en) * 2003-07-08 2005-01-27 The Scripps Research Institute Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity
WO2008073603A2 (en) * 2006-10-31 2008-06-19 The Scripps Research Institute Dosing regimen of activated protein c and variants having reduced anticoagulant activity

Also Published As

Publication number Publication date
US20190060421A1 (en) 2019-02-28
CN106573040A (zh) 2017-04-19
JP2017513944A (ja) 2017-06-01
EP3137102A4 (en) 2017-12-20
PL3137102T3 (pl) 2022-02-07
US20170042982A1 (en) 2017-02-16
DK3137102T3 (da) 2021-10-11
CA2946028A1 (en) 2015-10-22
ES2890675T3 (es) 2022-01-21
EP3137102B1 (en) 2021-07-14
CA2946028C (en) 2022-10-11
JP6846063B2 (ja) 2021-03-24
EP3137102A1 (en) 2017-03-08
AU2014391082A1 (en) 2016-11-03
PT3137102T (pt) 2021-09-28
US20200108128A1 (en) 2020-04-09
WO2015157791A1 (en) 2015-10-22
JP2020023519A (ja) 2020-02-13
US11491214B2 (en) 2022-11-08
AU2014391082B2 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
US11491214B2 (en) Treatment of abnormal cutaneous scarring
CN1961958B (zh) 改善伤口愈合的方法
AU2013312120B2 (en) Compositions and methods for treating cutaneous scarring
ES2676422T3 (es) Proteína C activada para su uso en el tratamiento de trastornos inflamatorios de la piel
US20250277010A1 (en) Agent for treatment of dermatological disorders
JP4351041B2 (ja) 傷治癒のための処置および組成物
US20150031633A1 (en) Bifunctional peptide
JP2004532892A6 (ja) 傷治癒のための処置および組成物
US12214024B2 (en) Use of APC analogue for wound healing
Kanno et al. α2‐Antiplasmin is involved in the production of transforming growth factor β1 and fibrosis
KR20220127880A (ko) 신경 손상 및 이의 관련 병증 치료 방법
HK1235306A1 (en) Treatment of abnormal cutaneous scarring
MXPA05007227A (es) Metodo para incrementar la fibronectina.
HK1235306B (zh) 治疗异常皮肤瘢痕形成
CN101541829A (zh) 来自丝光绿蝇的胰凝乳蛋白酶及其在治疗伤口中的用途
HK40047629A (zh) 皮肤病治疗剂
HK1230520B (zh) Apc类似物用於创伤癒合的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1235306

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant